1. Home
  2. USNA vs ZYME Comparison

USNA vs ZYME Comparison

Compare USNA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USNA
  • ZYME
  • Stock Information
  • Founded
  • USNA 1992
  • ZYME 2003
  • Country
  • USNA United States
  • ZYME United States
  • Employees
  • USNA N/A
  • ZYME N/A
  • Industry
  • USNA Medicinal Chemicals and Botanical Products
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • USNA Health Care
  • ZYME Health Care
  • Exchange
  • USNA Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • USNA 765.5M
  • ZYME 751.6M
  • IPO Year
  • USNA 1996
  • ZYME 2017
  • Fundamental
  • Price
  • USNA $33.43
  • ZYME $14.14
  • Analyst Decision
  • USNA Hold
  • ZYME Buy
  • Analyst Count
  • USNA 1
  • ZYME 6
  • Target Price
  • USNA $35.00
  • ZYME $19.17
  • AVG Volume (30 Days)
  • USNA 115.1K
  • ZYME 505.4K
  • Earning Date
  • USNA 02-04-2025
  • ZYME 10-31-2024
  • Dividend Yield
  • USNA N/A
  • ZYME N/A
  • EPS Growth
  • USNA N/A
  • ZYME N/A
  • EPS
  • USNA 2.83
  • ZYME N/A
  • Revenue
  • USNA $861,973,000.00
  • ZYME $62,199,000.00
  • Revenue This Year
  • USNA N/A
  • ZYME $21.53
  • Revenue Next Year
  • USNA N/A
  • ZYME N/A
  • P/E Ratio
  • USNA $11.79
  • ZYME N/A
  • Revenue Growth
  • USNA N/A
  • ZYME N/A
  • 52 Week Low
  • USNA $33.28
  • ZYME $7.97
  • 52 Week High
  • USNA $54.81
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • USNA 29.46
  • ZYME 52.72
  • Support Level
  • USNA $36.03
  • ZYME $12.48
  • Resistance Level
  • USNA $37.69
  • ZYME $14.10
  • Average True Range (ATR)
  • USNA 1.28
  • ZYME 0.72
  • MACD
  • USNA -0.51
  • ZYME 0.02
  • Stochastic Oscillator
  • USNA 2.40
  • ZYME 81.43

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: